Vaccines are important for protecting individuals at increased risk of severe infections,
including patients undergoing DMARD therapy. However, DMARD therapy can also …

Abstract Purpose of Review To review the impact of disease-modifying antirheumatic drugs
(DMARDs) on COVID-19 severity and vaccine immunogenicity and to discuss COVID-19 …

Objective To estimate the prevalence of patients with an immunocompromising condition at
risk for COVID-19, estimate COVID-19 prevalence rate (PR) and incidence rate (IR) by …

Background Solid organ transplant recipients have attenuated immune responses to SARS-
CoV-2 vaccines. In this study, we report on immune responses to 3rd-(V3) and 4th-(V4) …

Objective To provide guidance to rheumatology providers on the use of COVID‐19 vaccines
for patients with rheumatic and musculoskeletal diseases (RMDs). Methods A task force was …

Background There is a necessity for an optimal COVID-19 vaccination strategy for
vulnerable population groups, including people with autoimmune inflammatory arthritis on …

Objective The level of neutralising capacity against Omicron BA. 1 and BA. 2 after third
COVID-19 vaccination in patients on paused or continuous methotrexate (MTX) therapy is …

Background Sphingosine-one phosphate receptor (S1PR) modulation inhibits S1PR1-
mediated lymphocyte migration, lesion formation and positively-impacts on active multiple …

Methotrexate (MTX) is a readily accessible drug, first used in 1948 and employed for a wide
variety of indications since then. However, despite widespread off‐label use, FDA labeling …

Immune-mediated inflammatory diseases (IMIDs) are a highly heterogeneous group of
diseases that share a common etiology of immune dysregulation, such as rheumatoid …